Amarin (AMRN) Dips as Another Group DOESN'T Expect NCE

Amarin Corporation plc (NASDAQ: AMRN) dipped lower mid-day Thursday following a note from research firm Marwood Group that they don't expect NCE designation for the company's Vascepa.

According to a tweet from noted biotech watcher Adam Feuerstein of TheStreet.com:
@adamfeuerstein
Marwood Group Research report issued today predicting NO Vacepa NCE.

Shares of AMRN last traded at $12.40, down 0.2%

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Senate Committee Investigates Ozempic and Wegovy Costs - NYT
• Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
• Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB